Your browser is no longer supported. Please, upgrade your browser.
CBIO Catalyst Biosciences, Inc. monthly Stock Chart
Catalyst Biosciences, Inc.
Index- P/E- EPS (ttm)-3.10 Insider Own0.40% Shs Outstand22.07M Perf Week3.84%
Market Cap128.22M Forward P/E- EPS next Y-3.32 Insider Trans0.00% Shs Float21.09M Perf Month5.12%
Income-50.90M PEG- EPS next Q-0.78 Inst Own65.10% Short Float4.63% Perf Quarter16.67%
Sales18.90M P/S6.78 EPS this Y-71.50% Inst Trans1.08% Short Ratio4.11 Perf Half Y-19.49%
Book/sh4.26 P/B1.40 EPS next Y-34.40% ROA-45.80% Target Price- Perf Year9.58%
Cash/sh4.77 P/C1.25 EPS next 5Y- ROE-55.20% 52W Range3.43 - 8.94 Perf YTD-12.63%
Dividend- P/FCF- EPS past 5Y55.70% ROI- 52W High-33.45% Beta1.99
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin62.30% 52W Low73.47% ATR0.31
Employees21 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)60.41 Volatility3.39% 5.98%
OptionableYes Debt/Eq0.00 EPS Q/Q31.30% Profit Margin- Rel Volume0.25 Prev Close5.80
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume237.22K Price5.95
Recom2.00 SMA203.65% SMA5013.61% SMA2006.45% Volume59,086 Change2.59%
May-21-20Initiated Raymond James Outperform $20
Jan-04-19Initiated Oppenheimer Outperform $24
Feb-12-18Reiterated B. Riley FBR, Inc. Buy $19 → $49
Feb-09-18Reiterated Chardan Capital Markets Buy $37.50 → $75
Feb-09-18Reiterated Chardan Capital Markets Buy $10 → $75
Dec-08-17Initiated B. Riley FBR, Inc. Buy $19
Jun-12-17Initiated Chardan Capital Markets Buy $10
Jun-06-17Initiated Ladenburg Thalmann Buy $11
Jun-30-16Initiated Rodman & Renshaw Buy $3.50
Nov-25-20 10:15AM  
Nov-24-20 04:01PM  
Nov-12-20 08:50AM  
Nov-11-20 07:57AM  
Nov-05-20 09:00AM  
Nov-03-20 08:00AM  
Oct-14-20 10:17PM  
Oct-07-20 06:46AM  
Sep-25-20 08:00AM  
Sep-10-20 08:00AM  
Aug-06-20 08:00AM  
Jul-13-20 08:00AM  
Jul-09-20 09:48AM  
Jul-07-20 09:28PM  
Jul-01-20 04:48PM  
Jun-29-20 08:00AM  
Jun-22-20 04:05PM  
Jun-19-20 11:45AM  
Jun-18-20 09:00AM  
Jun-17-20 04:01PM  
Jun-15-20 08:00AM  
Jun-12-20 08:00AM  
Jun-10-20 08:00AM  
Jun-08-20 08:00AM  
May-11-20 08:00AM  
Apr-28-20 08:00AM  
Apr-21-20 10:53AM  
Apr-06-20 08:00AM  
Mar-29-20 09:02AM  
Mar-17-20 08:57AM  
Feb-24-20 08:00AM  
Feb-20-20 04:05PM  
Feb-18-20 04:05PM  
Feb-13-20 09:15AM  
Feb-12-20 04:15PM  
Feb-07-20 07:32AM  
Jan-27-20 08:00AM  
Jan-17-20 08:00AM  
Dec-30-19 01:12PM  
Dec-20-19 11:10AM  
Dec-19-19 09:34PM  
Dec-09-19 08:00AM  
Nov-12-19 08:00AM  
Nov-07-19 08:00AM  
Nov-06-19 08:00AM  
Oct-31-19 08:04AM  
Oct-04-19 10:08AM  
Oct-03-19 08:00AM  
Oct-02-19 09:00AM  
Sep-30-19 11:18AM  
Sep-27-19 09:00AM  
Sep-26-19 08:00AM  
Sep-25-19 11:14AM  
Aug-29-19 04:55PM  
Aug-20-19 01:49PM  
Aug-16-19 08:03AM  
Aug-08-19 08:00AM  
Aug-01-19 08:00AM  
Jul-26-19 08:00PM  
Jul-08-19 01:50PM  
Jul-02-19 11:53AM  
Jul-01-19 08:00AM  
May-28-19 08:00AM  
May-02-19 08:00AM  
Apr-29-19 08:05AM  
Apr-03-19 08:00AM  
Apr-02-19 08:00AM  
Apr-01-19 02:33PM  
Mar-08-19 09:48PM  
Mar-07-19 08:00AM  
Mar-06-19 08:00AM  
Feb-19-19 08:10AM  
Feb-08-19 08:00AM  
Feb-06-19 08:00AM  
Feb-05-19 08:00AM  
Jan-31-19 08:30AM  
Jan-22-19 02:21PM  
Jan-09-19 08:36AM  
Jan-08-19 07:20AM  
Dec-18-18 12:00PM  
Dec-10-18 08:00AM  
Dec-01-18 12:00PM  
Nov-21-18 11:56AM  
Nov-02-18 08:00AM  
Nov-01-18 08:00AM  
Oct-25-18 07:30AM  
Oct-24-18 08:00AM  
Sep-25-18 08:00AM  
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Levy HowardChief Medical OfficerMar 16Buy4.052,50010,1322,500Mar 17 04:23 PM
USMAN NASSIMPresident & CEOMar 13Buy3.914,00015,64711,010Mar 13 06:56 PM
Cai VeronicaControllerMar 13Buy4.112,0008,2207,353Mar 13 06:55 PM
Richard John PDirectorMar 13Buy3.982,5009,9503,716Mar 13 06:56 PM
Williams EddieDirectorMar 04Buy5.782,00011,56010,839Mar 04 04:18 PM
Ling Geoffrey M.D.DirectorFeb 25Buy6.233,00018,6923,000Feb 27 04:06 PM
LAWLOR AUGUSTINEDirectorFeb 25Sale6.1069,401423,5060Feb 25 04:21 PM